Biomarkers Journal Open Access

  • ISSN: 2472-1646
  • Journal h-index: 9
  • Journal CiteScore: 2.05
  • Journal Impact Factor: 7
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Short Communication - (2023) Volume 9, Issue 1

Properties of Antibiotics Acting against Infection
Joachim Paul*
 
Department of Medical Sciences, University of London, United Kingdom
 
*Correspondence: Joachim Paul, Department of Medical Sciences, University of London, United Kingdom, Email:

Received: 30-Jan-2023, Manuscript No. IPBM-23-16015; Editor assigned: 01-Feb-2023, Pre QC No. IPBM-23-16015 (PQ); Reviewed: 15-Feb-2023, QC No. IPBM-23-16015; Revised: 20-Feb-2023, Manuscript No. IPBM-23-16015 (R); Published: 27-Feb-2023, DOI: 10.35841/2472-1646.23.09.006

Introduction

Antibiotics are made for the kind of bacteria being treated and cannot generally be used to treat more than one infection. Antibiotics are typically safe and have few side effects when used correctly. Medical services suppliers can survey every patient exclusively to decide the right anti-microbial, portion and length of therapy. However, just like with the majority of drugs, antibiotics can cause side effects that range from minor to serious or even fatal. Antibiotic dosages may need to be adjusted for a variety of patient groups, including infants, the elderly, kidney or liver disease patients, pregnant or breastfeeding women, and many others. Antibiotics can also cause drug interactions to occur frequently. Not all infections can be treated with antibiotics. For instance, the majority of colds, sore throats, coughs, flu, COVID, and acute sinusitis are caused by viruses and do not require antibiotic treatment. These viral infections are “self-limiting,” which means that your own immune system will typically respond to the infection and eliminate it.

Description

Antibiotic resistance can develop when viral infections are treated with antibiotics. Even though an antibiotic may have been effective prior to the development of antibiotic resistance, it is unable to completely inhibit or eradicate antibiotic-resistant bacteria. If a secondary infection eventually necessitates the use of an antibiotic, this could also limit your options for effective treatments. Utilizing superfluous anti-toxins likewise endangers you for after effects and adds additional expense. Don’t give someone else your antibiotic, don’t take a medicine that was prescribed for you, and don’t keep an antibiotic for the next time you get sick. It may not be the right medication for your sickness. The spread of infections brought on by a variety of bacteria is a significant issue that poses a threat to human health. By clarifying the interactions of antibacterial compounds with the biological medium, this encourages scientists to discover novel treatments for these diseases. In this context, the chapter discusses some fundamental ideas regarding antibiotics. The combination courses of novel mixtures and explicit plan procedures with polymer materials are portrayed in connection with the in vitro and in vivo movement of antibacterial substances. Antibacterial medications kill bacteria. In vitro bacterial growth is slowed or stopped by bacteriostatic drugs. These definitions are not all-encompassing; some susceptible bacterial species may be killed by bacteriostatic drugs, and some susceptible bacterial species may only be inhibited in growth by bactericidal drugs [1-4].

Conclusion

The minimum in vitro concentration at which an antibiotic can kill or inhibit growth (minimum bactericidal concentration, or MBC) is determined using more precise quantitative methods. When host defences are impaired locally at the site of infection (such as in meningitis or endocarditis) or systemically (such as in patients who are neutropenic or immunocompromised in other ways), an antibiotic with bactericidal activity may enhance bacterial killing. However, based solely on that classification, there are insufficient clinical data to suggest that a bactericidal drug should be chosen over a bacteriostatic drug. Drug determination for ideal viability ought to be founded on how the medication fixation changes after some time comparable to the MIC as opposed to whether the medication has bactericidal or bacteriostatic action.

Acknowledgement

None.

Conflict of Interest

The author’s declared that they have no conflict of interest.

References

Citation: Paul J (2023) Properties of Antibiotics Acting against Infection. Biomark J. 9:006.

Copyright: © 2023 Paul J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.